Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Truist Financial Sticks to Their Buy Rating for Viatris (VTRS)

Tipranks - Tipranks - Sat Feb 28, 7:00AM CST

In a report released today, Les Sulewski from Truist Financial reiterated a Buy rating on Viatris, with a price target of $18.00.

Claim 50% Off TipRanks Premium

According to TipRanks, Sulewski is a 4-star analyst with an average return of 9.5% and a 47.27% success rate. Sulewski covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Cormedix, and Collegium Pharmaceutical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Viatris with a $14.86 average price target.

See today’s best-performing stocks on TipRanks >>

Based on Viatris’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.7 billion and a GAAP net loss of $340.1 million. In comparison, last year the company earned a revenue of $3.53 billion and had a GAAP net loss of $516.5 million

Read More on VTRS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).